Author

P. Pickford

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 6 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Assay:proteomics· 6 Organism:mouse· 4 Research Focus:cell signaling & trafficking· 3 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

A. Tomas· 7 shared B. Jones· 7 shared S. R. Bloom· 7 shared G. A. Rutter· 5 shared D. Hodson· 4 shared I. R. Correa· 4 shared M. Lucey· 4 shared T. M. Tan· 4 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersPharmacology & Toxicology

A. Tomas

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling

E. R. McGlone, Y. Manchanda, B. Jones, P. Pickford, A. Inoue, D. Carling, S. R. Bloom, T. M. Tan, A. Tomas

This study investigates how RAMP2 affects GCGR trafficking and signaling in hepatocytes, showing it alters receptor internalization and signaling bias with limited metabolic impact.

bioRxiv · May 9, 2021Cell Biology

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1

A. Marzook, S. Chen, P. Pickford, M. Lucey, Y. Wang, I. R. Correa, J. Broichhagen, D. Hodson, V. Salem, G. A. Rutter, T. M. Tan, S. R. Bloom, A. Tomas, B. Jones

This study compares the efficacy and affinity of two GLP-1R agonists, P5 and exendin-F1, showing that exendin-F1's lower acute efficacy correlates with sustained insulin secretion and anti-hyperglycaemic effects.

bioRxiv · Apr 1, 2021Pharmacology & Toxicology

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

P. Pickford, M. Lucey, R.-M. Rujan, E. R. McGlone, S. Bitsi, F. Ashford, I. R. Correa, D. Hodson, A. Tomas, G. Deganutti, C. A. Reynolds, B. M. Owen, T. M. Tan, J. Minnion, S. R. Bloom, B. Jones

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

bioRxiv · Mar 2, 2021Pharmacology & Toxicology

Signal bias at glucagon family receptors: rationale and downstream impacts

B. Jones, E. R. McGlone, Z. Fang, P. Pickford, I. R. Correa, A. Oishi, R. Jockers, A. Inoue, S. Kumar, F. Görlitz, C. Dunsby, P. M. French, G. A. Rutter, T. M. Tan, A. Tomas, S. R. Bloom

The paper investigates signal bias at glucagon family receptors, showing biased agonists affect intracellular signaling and insulin secretion differently.

bioRxiv · Apr 26, 2020Pharmacology & Toxicology

The influence of peptide context on signalling and trafficking of glucagon-like peptide-1 receptor biased agonists

Z. Fang, S. Chen, P. Pickford, J. Broichhagen, D. Hodson, I. R. Correa, S. Kumar, F. Gorlitz, C. Dunsby, P. French, G. A. Rutter, T. Tan, S. R. Bloom, A. Tomas, B. Jones

The paper evaluates how peptide context affects GLP-1R signaling and trafficking, showing differences in agonist-mediated responses based on sequence homology and structural features.

bioRxiv · Feb 24, 2020Pharmacology & Toxicology

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

M. Lucey, P. Pickford, J. Minnion, J. Ungewiss, K. Schoeneberg, G. A. Rutter, S. R. Bloom, A. Tomas, B. Jones

This study evaluates how C-terminal acylation affects GLP-1R signal bias and in vivo efficacy, finding that acylated ligands show improved therapeutic potential despite reduced potency.

bioRxiv · Nov 26, 2019Pharmacology & Toxicology

Differences in signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide

P. Pickford, M. Lucey, Z. Fang, S. Bitsi, J. Broichhagen, D. Hodson, J. Minnion, G. A. Rutter, S. R. Bloom, A. Tomas, B. Jones

This study compares the signalling, trafficking, and glucoregulatory effects of exendin-4 and lixisenatide, finding differences in cAMP signalling potency and receptor recycling that impact glucose control.

bioRxiv · Oct 16, 2019Pharmacology & Toxicology